FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025135170> ?p ?o ?g. }

• W3025135170 endingPage "1621" @default.
• W3025135170 startingPage "1612" @default.
• W3025135170 abstract "ObjectiveTo study the safety and tolerability of LymfactinⓇ treatment combined with microvascular lymph node transfer surgery in patients with upper limb lymphedema.BackgroundUpper limb lymphedema is a common clinical challenge after breast cancer surgery and/or radiotherapy. LymfactinⓇ is an adenovirus type 5–based gene therapy involving expression of human vascular endothelial growth factor C (VEGF-C) in the damaged tissue. It aims to correct deficient lymphatic flow by promoting the growth and repair of lymphatic vessels.MethodsIn Phase I, LymfactinⓇ was combined with microvascular lymph node transfer surgery to study the safety and tolerability of LymfactinⓇ and the biodistribution of the viral vector in patients with upper limb lymphedema.ResultsFifteen patients with breast cancer–associated secondary lymphedema of the upper arm were recruited between December 2016 and February 2018. Three patients received a lower dose (1 × 1010) and 12 a higher dose (1 × 1011) of viral particles, respectively. No dose-limiting toxicities were observed, and the study was completed with the pre-determined maximum dose. Commonly reported adverse events during the 12-month follow-up were common cold, fever, gastroenteritis, pain in the operation area, headache, muscle ache and elevated liver enzymes. Serious adverse events consisted of two erysipelas infections in the lymphedema arm (requiring hospitalization) and one hematoma of the flap donor site.ConclusionsAfter 12 months’ follow-up, results indicate that LymfactinⓇ is well tolerated. The study continues with a 36-months efficacy and 5 years safety follow-up of the patients. The oncological safety aspects of LymfactinⓇ will require a longer follow-up period." @default.
• W3025135170 created "2020-05-21" @default.
• W3025135170 creator A5010996325 @default.
• W3025135170 creator A5014269815 @default.
• W3025135170 creator A5023579230 @default.
• W3025135170 creator A5043255429 @default.
• W3025135170 creator A5048039348 @default.
• W3025135170 creator A5063057259 @default.
• W3025135170 creator A5080367673 @default.
• W3025135170 creator A5090381205 @default.
• W3025135170 date "2020-09-01" @default.
• W3025135170 modified "2023-10-01" @default.
• W3025135170 title "Phase 1 LymfactinⓇ Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema" @default.
• W3025135170 cites W1967292619 @default.
• W3025135170 cites W1990661960 @default.
• W3025135170 cites W1991298929 @default.
• W3025135170 cites W2003032824 @default.
• W3025135170 cites W2029895476 @default.
• W3025135170 cites W2031974429 @default.
• W3025135170 cites W2041259212 @default.
• W3025135170 cites W2044643954 @default.
• W3025135170 cites W2049708133 @default.
• W3025135170 cites W2052565600 @default.
• W3025135170 cites W2062108384 @default.
• W3025135170 cites W2065317648 @default.
• W3025135170 cites W2075713138 @default.
• W3025135170 cites W2079861804 @default.
• W3025135170 cites W2087455165 @default.
• W3025135170 cites W2102471792 @default.
• W3025135170 cites W2108828143 @default.
• W3025135170 cites W2122023472 @default.
• W3025135170 cites W2125150769 @default.
• W3025135170 cites W2127711761 @default.
• W3025135170 cites W2134774645 @default.
• W3025135170 cites W2160039361 @default.
• W3025135170 cites W2166793005 @default.
• W3025135170 cites W2166896143 @default.
• W3025135170 cites W2313308505 @default.
• W3025135170 cites W2331331798 @default.
• W3025135170 cites W2334000881 @default.
• W3025135170 cites W2473274532 @default.
• W3025135170 cites W2741988840 @default.
• W3025135170 cites W2753580919 @default.
• W3025135170 cites W2808201951 @default.
• W3025135170 cites W2900057342 @default.
• W3025135170 cites W2965670412 @default.
• W3025135170 cites W874628029 @default.
• W3025135170 doi "https://doi.org/10.1016/j.bjps.2020.05.009" @default.
• W3025135170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32513642" @default.
• W3025135170 hasPublicationYear "2020" @default.
• W3025135170 type Work @default.
• W3025135170 sameAs 3025135170 @default.
• W3025135170 citedByCount "32" @default.
• W3025135170 countsByYear W30251351702021 @default.
• W3025135170 countsByYear W30251351702022 @default.
• W3025135170 countsByYear W30251351702023 @default.
• W3025135170 crossrefType "journal-article" @default.
• W3025135170 hasAuthorship W3025135170A5010996325 @default.
• W3025135170 hasAuthorship W3025135170A5014269815 @default.
• W3025135170 hasAuthorship W3025135170A5023579230 @default.
• W3025135170 hasAuthorship W3025135170A5043255429 @default.
• W3025135170 hasAuthorship W3025135170A5048039348 @default.
• W3025135170 hasAuthorship W3025135170A5063057259 @default.
• W3025135170 hasAuthorship W3025135170A5080367673 @default.
• W3025135170 hasAuthorship W3025135170A5090381205 @default.
• W3025135170 hasBestOaLocation W30251351701 @default.
• W3025135170 hasConcept C121608353 @default.
• W3025135170 hasConcept C126322002 @default.
• W3025135170 hasConcept C141071460 @default.
• W3025135170 hasConcept C142724271 @default.
• W3025135170 hasConcept C181152851 @default.
• W3025135170 hasConcept C197934379 @default.
• W3025135170 hasConcept C2777129934 @default.
• W3025135170 hasConcept C2778375690 @default.
• W3025135170 hasConcept C2780849966 @default.
• W3025135170 hasConcept C2781392513 @default.
• W3025135170 hasConcept C530470458 @default.
• W3025135170 hasConcept C71924100 @default.
• W3025135170 hasConceptScore W3025135170C121608353 @default.
• W3025135170 hasConceptScore W3025135170C126322002 @default.
• W3025135170 hasConceptScore W3025135170C141071460 @default.
• W3025135170 hasConceptScore W3025135170C142724271 @default.
• W3025135170 hasConceptScore W3025135170C181152851 @default.
• W3025135170 hasConceptScore W3025135170C197934379 @default.
• W3025135170 hasConceptScore W3025135170C2777129934 @default.
• W3025135170 hasConceptScore W3025135170C2778375690 @default.
• W3025135170 hasConceptScore W3025135170C2780849966 @default.
• W3025135170 hasConceptScore W3025135170C2781392513 @default.
• W3025135170 hasConceptScore W3025135170C530470458 @default.
• W3025135170 hasConceptScore W3025135170C71924100 @default.
• W3025135170 hasIssue "9" @default.
• W3025135170 hasLocation W30251351701 @default.
• W3025135170 hasLocation W30251351702 @default.
• W3025135170 hasLocation W30251351703 @default.
• W3025135170 hasLocation W30251351704 @default.
• W3025135170 hasOpenAccess W3025135170 @default.
• W3025135170 hasPrimaryLocation W30251351701 @default.
• W3025135170 hasRelatedWork W1494361975 @default.

• next